The therapeutic options for treating psoriasis and atopic dermatitis have increased considerably in recent years, following the proliferation of biological drugs and small molecules. All these molecules have demonstrated greater efficacy and safety than traditional systemic drugs, improving the therapeutic management and quality of life of patients with inflammatory skin diseases. Many of these drugs have been demonstrated to be effective and safe in the long term.
The increase in effective treatments is accompanied by the clinician's difficulty in selecting the best treatment for the patient with an inflammatory skin disease. Direct comparisons between modern treatments are still scarce and involve only a few of these molecules. At present, no phenotypic characteristics that can confidently guide the clinician in the choice of treatment have been defined. Which biologic treatment is best for the metabolic syndrome patient? For the patient with oncological comorbidity? For the bio-naive patient? Which treatments are ideal according to the patient's age, comorbidity, and usual therapy? What is the correct sequence of treatments for a patient who goes through therapeutic failure?
The answer to these questions could allow us to better tailor the treatment to the peculiar characteristics of each patient. In this Research Topic, we accept articles such as original research, systematic reviews, reviews, hypothesis and theory, policy and practice reviews, and methods.
The therapeutic options for treating psoriasis and atopic dermatitis have increased considerably in recent years, following the proliferation of biological drugs and small molecules. All these molecules have demonstrated greater efficacy and safety than traditional systemic drugs, improving the therapeutic management and quality of life of patients with inflammatory skin diseases. Many of these drugs have been demonstrated to be effective and safe in the long term.
The increase in effective treatments is accompanied by the clinician's difficulty in selecting the best treatment for the patient with an inflammatory skin disease. Direct comparisons between modern treatments are still scarce and involve only a few of these molecules. At present, no phenotypic characteristics that can confidently guide the clinician in the choice of treatment have been defined. Which biologic treatment is best for the metabolic syndrome patient? For the patient with oncological comorbidity? For the bio-naive patient? Which treatments are ideal according to the patient's age, comorbidity, and usual therapy? What is the correct sequence of treatments for a patient who goes through therapeutic failure?
The answer to these questions could allow us to better tailor the treatment to the peculiar characteristics of each patient. In this Research Topic, we accept articles such as original research, systematic reviews, reviews, hypothesis and theory, policy and practice reviews, and methods.
